Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mapping Effector-Phenotype Landscapes in KRAS-Driven Cancers.

Trends in cancer - 1 May 2018

Winter Peter S, Wood Kris C

Abstract excerpt

Oncogenic KRAS can activate numerous effector pathways to drive malignant progression. However, the relationships between specific effectors and oncogenic phenotypes, and the extent to which these relationships vary across heterogeneous tumors, are incompletely understood. Recently in Cell Reports, a team of scientists described an innovative, combinatorial siRNA-based approach to functionally link KRAS effectors...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Line, Tumor
Share to KRAS gene
Share to Mutation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Oncogenes

Share to Phenotype

Share to Proto-Oncogene Proteins p21(ras)

Source

Identifiers

PMID: 29709255
DOI: 10.1016/j.trecan.2018.02.004

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mapping Effector-Phenotype Landscapes in KRAS-Driven Cancers.PMID 29709255Read ↗

Differential Effector Engagement by Oncogenic KRAS.Semantic proximity Read ↗

A Landscape of Therapeutic Cooperativity in KRAS Mutant Cancers Reveals Principles for Controlling Tumor Evolution.Semantic proximity Read ↗

Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants.Semantic proximity Read ↗

Defining the KRAS- and ERK-dependent transcriptome in KRAS-mutant cancers.Semantic proximity Read ↗

The KRAS-regulated kinome identifies WEE1 and ERK coinhibition as a potential therapeutic strategy in KRAS-mutant pancreatic cancer.Semantic proximity Read ↗

Synthetic Lethal Vulnerabilities in KRAS-Mutant Cancers.Semantic proximity Read ↗

EGFR blockade confers sensitivity to pan-RAS inhibitors in KRAS-mutated cancers.Semantic proximity Read ↗

Targeting the undruggable oncogenic KRAS: the dawn of hope.Semantic proximity Read ↗

KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance.Semantic proximity Read ↗

Overlapping and Distinct Functions of an Extended Repertoire of KRAS MutationsSemantic proximity Read ↗

RAS signaling and anti-RAS therapy: lessons learned from genetically engineered mouse models, human cancer cells, and patient-related studies.Semantic proximity Read ↗

Combinatorial strategies to target RAS-driven cancers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.